By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CardioDx, Inc. 

2500 Faber Place

Palo Alto  California  94303  U.S.A.
Phone: 650-475-2788 Fax: 650-475-2799



Start Up

Company News
Redwood City's CardioDx, Inc. Bags $21 Million As Biotech IPOs Hit Rough Patch 7/25/2014 6:59:27 AM
CardioDx, Inc. Announces Aetna And Coventry Health Coverage For Corus® CAD Gene Expression Test 7/8/2014 11:49:52 AM
CardioDx, Inc. Release: New Study Results Further Reinforce That The Corus® CAD Test Helps Primary Care Clinicians Make Effective Referral Decisions For Patients With Suspected Obstructive Coronary Artery Disease 5/5/2014 9:52:05 AM
CardioDx, Inc. Resurrects IPO Dreams 4/30/2014 8:18:29 AM
CardioDx, Inc. Announces New Leadership Appointments 4/28/2014 5:13:27 PM
CardioDx, Inc. And Medison Israel Enter Into An Exclusive Corus® CAD Product Marketing And Sales Agreement 4/9/2014 9:41:33 AM
CardioDx, Inc. Release: Study Finds the Corus® CAD Gene Expression Blood Test Influenced Primary Care Decision-Making In The Assessment Of Patients With Suspected Obstructive Coronary Artery Disease 3/11/2014 10:04:37 AM
CardioDx, Inc. Release: The Corus® CAD Gene Expression Test Can Help Commercial Health Plans Reduce Costs By Improving The Accuracy Of The Diagnostic Workup In Patients With Suspected Obstructive Coronary Artery Disease 2/26/2014 12:58:21 PM
CardioDx, Inc. Release: The Corus(R) CAD Gene Expression Test Significantly Correlates With Plaque Burden And Obstructive Coronary Artery Disease As Validated By CT-Angiography 2/3/2014 10:16:48 AM
CardioDx, Inc. Release: Results From REGISTRY 1 Study Confirm Clinical Utility Of Corus® CAD Genomic Test In Optimizing Care In Elderly Patients Presenting To The Primary Care Clinician With Symptoms Suggestive Of Obstructive Coronary Artery Disease 11/25/2013 7:34:27 AM